Molecular Analysis of 150 Lung Adenocarcinoma
This trial is active, not recruiting.
|Sponsor||Hospices Civils de Lyon|
|Start date||January 2014|
|End date||January 2016|
|Trial size||152 participants|
|Trial identifier||NCT02843711, 69HCL15_0161|
LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas. For all patients, clinical data and histopathological data are available. The objective of this study is to characterize these lung adenocarcinomas by the LungCarta Panel using the mass spectrometry array Sequenom. This panel could identify 214 DNA mutations and/or frameshift insert/deletion among 26 oncogenes. Once included in the study, the adenocarcinomas are also included in a Tissue MicroArray (TMA) in order to perform immunohistochemical analysis. Immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data.
Our hypothesis is that this TMA could constitute a good tool to screen interesting protein's expression.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
Genomic DNA Mutation
time frame: at diagnosis (Day 0)
Male or female participants from 18 years up to 99 years old.
Inclusion Criteria: - Adults - lung adenocarcinoma - Surgical specimen Exclusion Criteria: - not adenocarcinoma subtype of lung cancer - Tumour biopsy - insufficient material for DNA extraction
|Official title||Molecular Analysis of 150 Lung Adenocarcinoma With Corresponding Histopathological and Clinical Data Available|
|Principal investigator||Marie BREVET, MD|
Call for more information